Evidence map›Paper›PMID 41111097›Full record

ArticlePrevention science : the official journal of the Society for Prevention Research2026

Development and Validation of an Electronic Health Record-Derived Prediction Model for Preventing COVID-19 Hospitalization and Death.

R Yates Coley, Rachel Hays, Roy E Pardee, Sharon Fuller, Kristine Rogers, Claire L Allen, David E Arterburn, Robert K Frazier, Daniel J Kent, Sophia Mun and 3 more

Abstract readValidation Study
In one paragraph

Article in Prevention science : the official journal of the Society for Prevention Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

R Yates ColeyKaiser Permanente Washington Health Research Institute, Seattle, WA, USA. rebecca.y.coley@kp.org.ORCID http://orcid.org/0000-0003-1708-4880
Rachel HaysKaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
Roy E PardeeKaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
Sharon FullerKaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
Kristine RogersKaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
Claire L AllenKaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
David E ArterburnKaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
Robert K FrazierKaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
Daniel J KentKaiser Permanente Washington, Seattle, WA, USA.
Sophia MunKaiser Permanente Washington Health Research Institute, Seattle, WA, USA.
Tolani MwathaKaiser Permanente Washington, Seattle, WA, USA.
Paul ThottingalKaiser Permanente Washington, Seattle, WA, USA.
Emily O WestbrookKaiser Permanente Washington Health Research Institute, Seattle, WA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hospitalization and death following COVID-19 infection continue to pose a major public health concern and place strain on health system resources. Outpatient antiviral medication can reduce the risk of COVID-19 hospitalization and death for those at risk of poor outcomes, but identifying high-risk populations who may benefit most from treatment is challenging. The objective of this study was to develop and validate a prediction model for the composite outcome of hospitalization or death in the 14 days following COVID-19 infection. Our sample included 67,530 COVID-19 infections documented in outpatient care and occurring between April 1, 2020, and November 1, 2022, for 64,529 Kaiser Permanente Washington patients who did not receive outpatient antiviral treatment; 1378 (2.0%) of these infections resulted in hospitalization or death. Our prediction model, estimated using logistic regression with LASSO variable selection and ridge penalization, included 19 risk factors and showed high performance, including an area under the curve of 0.825 (95% confidence interval 0.813-0.836). Among the 10% of infections with the highest risk predictions, the true positive rate was 48% (46-51%) and the positive predictive value was 9.9% (9.2-10.6%). Supplemental analyses confirmed strong model performance across racial and ethnic subgroups and over time. We also present our process for selecting a risk threshold above which to recommend antiviral treatment and discuss considerations for prospective clinical implementation. This project demonstrates that machine learning tools can be used by health systems to deliver timely, targeted secondary prevention to reduce the risk of serious illness or death.

Indexed as

COVID-19Electronic Health RecordsHospitalizationAdultAgedFemaleHumansMaleMiddle AgedPrediction AlgorithmsRisk FactorsSARS-CoV-2WashingtonAlgorithm fairnessClinical prediction modelHealth equityLearning health systemNirmatrelvir/ritonavir (Paxlovid®)Prospective validation

Identifiers

PMID41111097
PMCPMC13550066

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.